Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Hepatitis B Virus (HBV) Market Expected to Be in 2029?

In recent times, the market for the hepatitis B virus (HBV) has seen robust expansion. It is set to grow from $6.71 billion in 2024 to $7.31 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.9%. The growth observed in the historic period is credited to factors such as the increasing prevalence of hepatitis b virus (hbv), a growing need for hbv diagnostics, broader hbv vaccine coverage, and heightened awareness of the hepatitis b virus (hbv).

The market size for the hepatitis B virus (HBV) is projected to witness robust expansion in the following years. It is set to increase to “$10.59 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.7%. Factors driving this growth in the projected period include the surge in personalized medical treatments, growing assistance from patient support groups, escalating vaccination initiatives, and an upturn in healthcare spending. The forecast period will also see key trends such as the introduction of new pharmaceuticals, advancements in diagnostic technology, collaborative efforts between public and private sectors, and innovative biological therapy methods.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12867&type=smp

What Are The Contributors To Demand In The Hepatitis B Virus (HBV) Market?

The hepatitis B virus market is anticipated to be driven by the high incidence of hepatitis B infections. Hepatitis B is a liver disease caused by the hepatitis B virus (HBV) and can be immunized against. The escalating rate of hepatitis B infections can stimulate requirements for diagnostic examination and treatment interventions. For instance, the World Health Organization, a Switzerland-based intergovernmental organization reported in April 2024, that in 2022, there were 254 million chronic hepatitis B infected individuals with an addition of 1.2 million new cases every year. Therefore, the high prevalence of hepatitis B infections is expected to fuel the hepatitis B virus market.

The hepatitis b virus (hbv) market covered in this report is segmented –

1) By Type: Acute, Chronic

2) By Treatment: Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery

3) By Age Group: Pediatrics, Adults, Seniors

4) By End User: Medical Providers, Patients, Healthcare Payers

Subsegments:

1) By Acute HBV: Asymptomatic Acute HBV, Symptomatic Acute HBV, Severe Acute HBV

2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive), Chronic Hepatitis B (HBeAg Negative), Chronic Hepatitis B With Compensated Liver Disease, Chronic Hepatitis B With Decompensated Liver Disease, Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)

Which Emerging Trends And Strategic Shifts Are Shaping The Hepatitis B Virus (HBV) Market?

Major firms involved in the Hepatitis B Virus (HBV) market are concentrating on creating innovative diagnostic and treatment alternatives such as using the highly sensitive Chemiluminescent Microparticle Immunoassay (CMIA) to gain an edge in the market. For example, Abbott Laboratories, an American healthcare corporation, introduced the HBsAg Next Qualitative Solution Test in May 2022. This will enhance early detection of HBV in human serum and plasma samples, improve patient health outcomes, and maintain reliable blood supplies. This extremely sensitive Chemiluminescent Microparticle Immunoassay (CMIA) allows both early HBV detection in human plasma and serum samples, and population-level screening.

Who Are The Top-Ranked Companies In The Hepatitis B Virus (HBV) Market Today?

Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmon La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Eisai Co. Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Celltrion Inc., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Globeimmune Inc., Antios Therapeutics Inc.

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

How Is Hepatitis B Virus (HBV) Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the hepatitis B Virus (HBV) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis B virus (HBV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12867&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model